IL6 and chronic kidney disease: Considering the promising evidence from clinical trials targeting inhibition of interleukin-1 and interleukin-6-mediated pathways in patients with atherosclerosis and CKD, the identification of specific immune phenotypes associated with myocardial dysfunction in the setting of CKD would be of major clinical significance [34].